Member Info for BertieBassett

I believe we already do have one ... ?

nasdaq.com/market-activity/stocks/iqaif

-- BB --

From TB in RNS ... "our patented artificial intelligence technology" ... AI tech ... is the now and future ...

Medical AI (and education) is leading the way.

-- BB --

Https://mailchi.mp/imagingbiometrics/ib-newsletter-edition-17568243

--BB--

Https://twitter.xxx/IQAI_IB/status/1699801486405038497

The primary goal of the EAF151 Phase II multi-site trial is to evaluate if @IQAI_IB 's DSC MRI (IB Neuro) can non-invasively predict which recurrent GBM patients will respond to Bevacizumab – optimizing treatment on a personalized level!

-- BB --

A huge shout out to the @eaonc ACRIN/ECOG EAF151 team for completing trial accrual! EAF151 is the FIRST trial of its kind – with a goal to evaluate an advanced MRI biomarker for brain tumors. DSC perfusion imaging (@IQAI_IB's IB Neuro) was their choice.

-- BB --

It's just a matter of time now.

AI is the present and future.

--BB--

Https://twixxer.com/Heidyll/status/1697603106333208589

-- BB --

Https://twitter.com/Heidyll/status/1697603106333208589

-- BB --

Https://mailchi.mp/imagingbiometrics/webinardeltat1-maps-defined-with-examples-of-clinical-utility-17341939

September 19th

- Overview of the hardware and software requirements to integrate IB Clinic.

- Recommended steps to implement IB Clinic within the clinical workflow.

- Overview of IB Clinic output map Options (i.e. rCBV, Delta T1).

- Real-life examples of successful integration of IB Clinic into clinical workflows

-- BB --

Https://twitter.com/IQAI_IB/status/1694762841121902843

Collaboration is key to expanding reach and improving patient outcomes! IB's tools are available on the Blackford and Bayer Calantic Platforms!

** NOT just GE in the mix **

-- BB --

Further to the RNS dated 8 February 2022, IQ-AI Ltd (LSE: IQAI, OTCQB: IQAIF) announces that the collaboration agreement signed with the Mayo Clinic for the development of IB Trax™ has concluded. The working relationship with the Mayo Clinic remains unchanged and will continue. As a corollary of the conclusion of the agreement, and in the spirit of the long-standing and continuing relationship between both parties, The Mayo Foundation has reverted the 396,241 shares previously issued to them per the terms of the agreement, and the Company has agreed with its Broker, Peterhouse Capital, to sell these shares in the market and to donate the entirety of the proceeds to charity.

-- BB --

1) In February 2023, it was announced GE HealthCare has acquired the San Mateo-headquartered AI medical technology manufacturer, Caption Health, for an undisclosed sum.

2) Total assets GEHC US$27.5 billion (2022)

3) GE Health has installed 4 million scanners and other medical devices worldwide!

-- BB --

Imaging Biometrics, LLC (IB), a wholly-owned subsidiary of IQ-AI Ltd (LSE: IQAI, OTCQB: IQAIF), is pleased to announce that it has entered into a commercial agreement with GE HealthCare ('GEHC'). The agreement makes IB's products available on GEHC's MR Smart Subscription.

IB Neuro and IB Delta T1 maps are applications that accept magnetic resonance imaging (MRI) data as input and automatically compute quantitative and proprietary images as output.

The global MRI market is projected to grow at a rate of 7% and surpass $11 billion by 2030, and GEHC is a leading player in that market. A factor driving that growth are complementary advancements in imaging software, such as IB's quantitative solutions. [1]

The agreement will make IB's solutions available directly to the large number of sites with GEHC systems already installed as well as new systems scheduled for installation. Ultimately, this agreement streamlines clinical adoption of IB's solutions and represents a potential transformational step-change in business activity for IQAI.

"This agreement with GEHC is a major development for IQAI," said Trevor Brown, CEO of IQ-AI. "It means that any hospital or imaging center that has a GEHC MRI scanner and MR Smart Subscription will have access to IB's solutions."

-- BB --

& on Twitter:

https://twitter.com/IQAI_IB/status/1688580763841941505/photo/1

-- BB --

Https://www.linkedin.com/company/imaging-biometrics-llc/posts/?feedView=all

-- BB --

Worth a read: https://spectrumnews1.com/wi/milwaukee/news/2023/06/16/clinical-trial-in-wisconsin-looks-to-tricks-brain-cancer-cells--slow-tumor-growth

-- BB --

If this is not a "buy us" alert, what is??

-- BB --

Imaging Biometrics, LLC (IB), a wholly-owned subsidiary of IQ-AI Ltd (LSE: IQAI, OTCQB: IQAIF), today announced the U.S. Food and Drug Administration (US FDA) has granted Orphan Drug Designation (ODD) for gallium maltolate (GaM) for the treatment of pediatric glioblastoma multiforme (GBM).

WHOOHOO!

-- BB --

"In April, IB applied for Orphan Drug Designation to the US Food and Drug Administration (FDA) for the use of GaM in pediatric brain tumors. The application is under review and, if granted, would support the development and evaluation of a new treatment alternative for an unmet clinical need."

How long did it take for the last IB - FDA application to go through?

thanks

-- BB --

Https://youtu.be/LE_xkY6k3S0